Institute of Haematology
The Institute of Haematology Research Unit is a leader in both clinical and laboratory research spanning malignant and non-malignant haematology. Our clinical trials unit has been very active in multiple diseases over many years, investigating and making available many state-of-the-art agents and protocols for our patients. Our laboratory research unit has concentrated on basic research into the immunology and molecular pathophysiology of myeloma, the molecular basis and monitoring of acute promyelocytic leukaemia and myeloproliferative diseases, the immunological aspects of transplantation and immunotherapy, and the pathophysiology and laboratory assays to monitor the treatment of clotting disorders.
RPA Haematology has been highly active in clinical trials over many years, and is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology. Our clinical trial activity covers a wide portfolio - myeloma in all stages of disease, acute myeloid and lymphoblastic leukaemia, acute promyelocytic leukaemia, numerous subtypes of lymphoma (eg. diffuse large B cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and primary CNS lymphoma), chronic lymphocytic leukaemia, myelofibrosis, myelodysplasia, allogeneic stem cell transplantation, haemophilia, haemoglobinopathies and iron overload.
In the last 3 years we have had 28 active clinical trials, screened 450 and enrolled 216 patients, including the opening of 16 trials in 2018. The majority of the collaborative group trials are carried out under the auspices of the Australasian Leukaemia and Lymphoma Group, of which the RPA Haematology team are key members.
Main areas of interest in our group are myeloma, acute promyelocytic leukaemia, blood & marrow transplantation, the haemoglobinopathies and clotting disorders, for which our unit has been considered the leading sites of investigative studies. Key members of our staff have taken a leadership role as chief investigators at a national level in many of these trials, including Prof Joy Ho's ALLG MM16 trial, and Prof Harry Iland's ALLG APML5 trial, which both employ novel state-of-the-art compounds and strategies.
The APML5 trial is a follow-on study from the APML4 trial, which has revolutionized the care and outcomes for patients with high-risk APL by demonstrating that intravenous arsenic trioxide can be successfully incorporated into the standard ATRA + chemotherapy backbone for frontline therapy. The final analysis of the APML4 trial was selected for oral presentation at the American Society of Hematology Annual Scientific meeting in December 2014, and was published in Lancet Haematology in 2015. The longer follow-up demonstrated significantly improved overall survival compared with Prof Iland's previous ALLG APML3 trial that did not include arsenic. APML4 has proved to be practice-changing both in Australia and internationally. The importance of the APML4 regimen for Australian patients is underscored by several major achievements:
• APML4 has been included as a preferred regimen in the US National Comprehensive Cancer Network's recommendations for the treatment of high-risk APL
• APML4 has been recommended for the treatment of high-risk APL by a panel of Canadian APL experts
• Data from the APML4 trial were instrumental in the registration of arsenic trioxide by the Therapeutic Goods Administration for the front-line therapy of APL, and for subsequent inclusion in the Pharmaceutical Benefits Scheme.
It is noteworthy that Australian patients with previously untreated APL were able to access arsenic therapy before that approval was extended to North American and European patients, and arsenic is available for Australian patients with all risk categories of APL, whereas its use in North American and Europe is restricted to patients with standard-risk disease.
Prof Iland's recently activated APML5 trial is a phase I pharmacokinetic study of a novel oral arsenic formulation, and has already generated considerable interest in North America. If the oral formulation of arsenic trioxide proves to be efficiently absorbed without additional toxicity, it has the potential to significantly alter current practice in the treatment of APL by dramatically reducing hospital resources and patient inconvenience. Part (i) of APML5, which sought to characterise the bioavailability profile of the oral formulation, has been completed successfully. Part (ii), which will provide confirmatory data for the oral dose, has been opened to accrual and registration of patients has commenced. Prof Iland was invited to present the APML4 and APML5 trials at the 7th International APL Symposium in Rome in September 2017, and an abstract reporting the part (i) findings of APML5 has been submitted to the 2019 European Haematology Association annual scientific meeting.
Prof Iland's contributions to the management of APL have been acknowledged internationally; he was invited to contribute a chapter on the management of APL for a new textbook specifically dedicated to APL, and he is an invited member of the European LeukemiaNet's panel of international APL experts which has recently published revised guidelines for the diagnosis and management of APL.
In myeloma, Prof PJoy Ho is the Principal Investigator (PI) of the ALLG MM16 trial, a multicentre ALLG study which investigates the early kinetics of serum free light chains (SFLC) as a predictor of reversal of renal impairment, a key adverse prognostic factor in myeloma, utilising the novel proteasome inhibitor Carfilzomib. Results from a planned interim analysis performed in mid- 2018 was accepted for presentation at the American Society of Hematology Annual Scientific meeting in December 2018. Our results demonstrated the value of early SFLC kinetics in predicting renal response, providing a new strategy of management - the utilisation of a suboptimal early SFLC measurement at specific time points as an indicator of poor renal prognosis to effect a change in therapeutic strategy by increasing dose density or change of agent may prevent patients from developing irreversible, dialysis-dependent renal failure. This finding has significant implications on patient prognosis and survival. We also showed that Carfilzomib and dexamethasone achieved comparable disease response rates in patients with renal failure as compared with normal renal function, with no increase in adverse events - a crucial finding due to concerns of increased toxicity of this novel agent in this subgroup of vulnerable patients, including the exacerbation of acute kidney injury.
RPA has been a key site in major myeloma trials in the newest agents and treatment protocols, including carfilzomib, daratumumab as an immunotherapy, being a first-in-class antibody against CD38, and venetoclax. We have now initiated two phase I studies (1) a bi-specific antibody against CD38 and CD3, and (2) an Mcl-I inhibitor, with Prof Joy Ho as PI. These studies provide crucial opportunities for our patients to receive agents at the cutting edge of myeloma research. In addition a large number of Phase II and III trials continue to be conducted at every stage of myeloma - at diagnosis and various stages of relapse.
Prof Ho and Joshua are active members of the International Myeloma Working Group (IMWG). The RPAH Myeloma Group was the first NSW site to join the national Myeloma and related Diseases Registry (MRDR) and is one of the highest recruiters in the registry. RPA Haematology was one of only 2 Australian sites selected for a multinational trial on Chimeric Antigen Receptor (CAR)-T cells in relapsed diffuse large B cell lymphoma, using a CAR-T directed against CD19. This study, with Prof Ho as PI, was the first study utilising this state-of-the-art immunotherapy in our unit, and the first clinical trial of this nature in Australia. Precise and careful coordination between multiple sections of our department ranging from apheresis, cell therapies and clinical in-patient and out-patient staff, as well as cooperation with emergency and ICU colleagues have been established to ensure successful conduct of this seminal trial, bringing a ground-breaking therapy to Australia.
Due to the success of this trial, a second CAR-T trial in follicular lymphoma has been initiated, and RPA Haematology has been selected as one of the first Australian sites for non-trial CAR-T therapy for diffuse large B cell lymphoma. We have also been selected as one of 2 Australian sites for a Phase I clinical trial into allogeneic "off-the-shelf" CAR-T cells in lymphoma, which we anticipate will be activated in 2019. If successful, development in this field will significantly increase the possible applications of CAR-T therapy, being no longer dependent on autologous T cell collection. We are also being actively being considered for CAR-T trials, both autologous and allogeneic, in myeloma.
The RPAH Blood and Bone Marrow Transplantation (BMT) group, led by Prof John Gibson and A/Prof Stephen Larsen, has also been highly active in clinical trials. In collaboration with other NSW allogeneic BMT centres we are key participants of a clinical trial assessing the safety and efficacy of a myeloablative conditioning regimen for haploidentical allogeneic transplants, as well as an important project that aims to standardise conditioning regimens for allogeneic BMT in acute myeloid leukaemia patients. We are also participating in an ALLG trial exploring reduced intensity conditioning in patients with acute myeloid leukaemia between the ages of 51 and 70, and in a large clinical project exploring long-term follow-up care of BMT patients. Our unit is a major contributor to both national and international registries.
Prof Gibson is a member of 3 scientific sub-committees - in myeloma, lymphoma, and graft manipulation. In addition to ongoing accreditation by the Australian Blood and Marrow Donor Registry (ABMDR) and the Centre for International Blood and Marrow research (CIBMTR), our transplant service is the only NSW service accredited by the Therapeutic Good Administration (TGA). In the "non-malignant" aspects of haematology, our Unit has been an instigator of national clinical trials on the impact of iron overload on haematological disease, including not only the Haemoglobinopathies but also the myelodysplastic syndromes (MDS) and myeloproliferative neoplasia (MPN).
Firstly a multi-centre clinical study led by Prof Ho on the effect of an oral iron chelator on cardiac iron, assessed by state-of-the-art technology of cardiac MRI with T2* quantitation in conjunction with MRI assessment of liver iron was conducted and presented at both American Society of Hematology and European Hematology Association meetings, and published in European Journal of Hematology in 2017. Secondly and more recently, a multi-centre national epidemiological study on the prevalence of cardiac and hepatic iron load in transfusion-dependent anaemias and non-transfusion-dependent thalassaemia (NTDT), including transfusion-dependent malignant diseases, was also led by Prof Ho.
It established the impact of iron toxicity on disease course, and was a major achievement in the integration of improved disease monitoring by cardiac and liver MRI monitoring with innovations in management, in both inherited and acquired transfusion-dependent anaemia. Using correlations between MRI findings and blood parameters, this study enabled a much needed assessment of the effectiveness and accuracy of various methods of iron assessment across the different disease groups. The findings were selected for oral presentation at the American Society of Hematology Annual Scientific meeting in December 2015, and the manuscript has been accepted for publication in Hemasphere, Journal of the European Hematology Association. In addition, in thalassemia, we are currently performing 2 state-of-the-art clinical trials with Prof Ho as principal investigator.
In a multi-national trial of Luscpatercept, a fusion protein of an activin receptor and immunoglobulin G which corrects ineffective erythropoiesis and reduces transfusion dependence, RPA Haematology was the lead Australian investigative site for the number of patients treated; the study has been presented at both the American Society of Hematology and European Society of Hematology scientific meetings in 2018. Secondly, a Phase I/II study of hepcidin is currently in progress; hepcidin is the "hormone" that is suppressed in thalassemia patients, leading to increased iron toxicity. RPA Haematology was again the lead investigative site with the highest number of patients participating in Australia. In haemophilia, under the leadership of Drs Dunkley and Khoo, the unit is participating in many international clinical trials utilising state-of-the-art products in patients with inherited bleeding disorders. Trials involving the extended half-life (EHL) factor VIII and IX products have dramatically improved the quality of life of these patients, who now only administer injections once a week compared with three times a week in the past. Dr Khoo is supervising an MD student examining the quality of life, factor consumption and PK results in these patients on EHLs. In addition, the haemophilia centre has been involved in clinical trials using non-factor replacement therapies.
An ongoing clinical trial is being conducted with Emicizumab, a humanised monoclonal antibody that has revolutionised the treatment of haemophilia complicated by the development of inhibitors, using a subcutaneous injection once a week. Results of this trial has been presented at American Society of Hematology and the European Society of Haemophilia meetings. The unit is also involved in a clinical trial using Fitusiran, a novel siRNA against Anti-thrombin III. The rationale behind this treatment strategy in patients with haemophilia is to rebalance the haemostatic system. In 2019, Drs Dunkley and Khoo are part of an international ground breaking study using gene therapy using the AAV5 virus to treat and potentially cure patients with haemophilia. Mr Geoffrey Kershaw (senior hospital scientist and coagulation lead) in conjunction with Drs Dunkley, Chen (from Concord Hospital) and Khoo are also conducting several investigator-initiated field studies in Australian haemophilia laboratories to review FVIII and FIX measurements for the new extended half-life FVIII product. Results from these studies will allow all Australian Haemophilia centres to have experience in measuring these products and optimising their laboratory assays. These studies have the support of the AHCDO (Australian Haemophilia Centre Directors Organisation) research committee. Drs Dunkley and Khoo are also collaborating with the physiotherapy department (Mr Joshua Wakefield and Mr Joshua Hutton)and rheumatology department as part of a multidisciplinary group examining the role of hydrotherapy in bleeding disorders.
Our unit is also a pioneer in promoting research in supportive care in haematological nursing, with specialty nurses conducting research in myeloma and health related quality of life (HRQoL). Tracy King is a clinical research fellow within Cancer Nursing Research Unit, Sydney University and collaborates with the wider nursing team on various research projects. Tracy and Eleanor Romney are conducting the 'Patient-reported outcomes in multiple myeloma: real-time reporting to improve care(My-PROMPT) PI's T King & PJ Ho' in collaboration with School of Public Health and Preventative Medicine, Monash University Myeloma and Related Disease Registry; Tracy King and Eleanor Romney are collaborating with Sydney University Brain and Mind Institute on the IN FOCUS study assessing Chemotherapy Induced Peripheral Neuropathy; Tracy King is conducting the 'Financial Impact of Cancer and its Treatment on Australian Haematology Patients and their Families (Fin-Tox Study) for which she was awarded a NSW Ministry of Health Nursing and Midwifery Innovations Scholarship ($15,000) and the 'Development and evaluation of a patient reported outcome measure (PROM) to assess the impact of steroids associated with therapy for myeloma' as her ongoing PhD research . These studies have resulted in several abstract presentations in HAA/IMW/MASCC meetings. Tracy King is an affiliate member of the International Myeloma Foundation Nurse Leadership Board and co-chair of the nursing program within the International Myeloma Workshop Boston USA 2019.
Laboratory and Translational Research
In many haematological diseases, our work in the laboratory is highly complementary to our clinical research and our very busy clinical practice. Our unit has been heavily involved in the investigation of the immune and molecular pathophysiology of myeloma, and is widely considered an Australian pioneer in examining the immunological basis of myeloma, with enormous impact on current developments in immunotherapy. Recent work has focused on the precise phenotype of clonal T cells, defining the mode of telomere-independent senescence, with likely implications on the use of CAR-T therapy and other strategies of immunotherapy in myeloma. Continuing work on the dysfunctional immune system, dysregulated signaling pathways, T regulatory cells, trogocytosis, checkpoint inhibition, long-term survivors and targets for novel therapies including cancer stem cells will have significant impact on new therapies.
Our previous research performed within the Multiple Myeloma Research Group demonstrated that T cells in Myeloma and Waldenstrom's Macroglobulinemia (WM) exhibit considerable skewing of the T cell repertoire (Leuk. Lymphoma 2003;441667-1674; Leukemia 2016;30:1716-24; Blood 2010;115:3580-3588), that is, particular subsets of T cells with specific target receptors (known as Vβ receptors) are more prominently represented in myeloma and WM patients. This discovery raises new fundamental questions that we continue to explore in our ongoing research. Since 2017, our major focus has been to determine whether this "prominence" of specific groups of T cells represents the selective proliferation of T cells with protective anti-myeloma immunity or are due to underlying T-cell defects as a result of the tumor burden and/or the ageing process.
As the bone marrow is the tumour microenvironment of myeloma, we explore whether the marrow microenvironment provides a unique site for the skewing of the VβT-cell receptor repertoire and shaping immune responses as compared with peripheral blood. We still do not know at which stage of myeloma progression that the natural myeloma immunosurveillance becomes activated or idefective. Hence we are exploring how these changes may evolve through the premalignant stage of multiple myeloma - monoclonal gammopathy of undetermined significance (MGUS) as well as smouldering myeloma, which precedes symptomatic myeloma.
To execute the research in a unique and innovative way, the Myeloma Research group under Prof P Joy Ho and lead scientist Dr Slavica Vuckovic has established collaborations with research teams in the Garvan Institute of Medical Research and the Charles Perkins Centre. Through these collaborations we have started to use multi-scale analytical approaches - single-cell RNA sequencing and CyTOF Mass cytometry for high-dimensional phenotypic analysis of single cells.
One of the challenges in the field of plasma cell dyscrasia and myeloma is to understand which factors keep MGUS clinically stable, and what critical events allow permissive expansion of malignant plasma cells which may lead to the progression of myeloma. This is particularly perplexing as MGUS patients have already been shown to have increased infiltration of T cells in the bone marrow, as well as frequent TCR-Vβ expansions indicative of ongoing immune responses, and genetic changes similar to myeloma patients. Our resent research provides an exciting novel discovery which may help to resolve this mystery. We found that discrete subsets of T regulatory cells allow discrimination between MGUS and newly diagnosed myeloma patients.
The use of mass cytometry has enabled the interrogation of the T regulatory cell compartment of MGUS and newly diagnosed myeloma patients at high resolution and facilitated the discovery of these discrete subsets of T regulatory cell (manuscript submitted March 2019). It is expected that our innovative research will make a major contribution to myeloma treatment, aiming to intervene in natural immunosurveillance to potentially eliminate myeloma or maintain myeloma in long lasting remission.
Investigations into the molecular basis of myeloma has led to new insights in the role of FGFR3 a key candidate gene in the t(4;14) translocation, and more recent work established digital PCR in the detection of minimal residual disease, and the role of other candidate gene expression on disease behaviour. Through the years, our work has revealed the multi-faceted nature of myeloma pathogenesis. For example in the ALLG MM6 study investigating the role of thalidomide in consolidation after autologous transplantation, our work in both immunological and molecular aspects revealed the importance of T cell clones as well as the expression of one of the key candidate genes FGFR3 in the translocation t(4;14) in predicting disease outcome.
The Molecular Haematology Laboratory provides a comprehensive diagnostic service for the detection and quantitation of gene mutations in patients with myeloid malignancies. Members of the Molecular Laboratory have utilised their expertise to identify novel variants of acute promyelocytic leukaemia (the PRKAR1A-RARA rearrangement - Dr Alberto Catalano) and core binding factor acute myeloid leukaemia (the type J variant of the CBFB-MYH11 rearrangement - Ms Francisca Supple). Patients with non-malignant disorders are also studied, and this work has led to the recognition of a novel XK gene mutation in a patient with the McLeod syndrome (Dr Shane Supple).
The range of available tests is continually being expanded as knowledge about the pathogenesis of leukaemias and myeloproliferative disorders increases, and this activity was accelerated by the recruitment of a Fellow in Molecular Haematology (Dr Derek McCulloch) in 2016-2017. Further expansion of the department's diagnostic repertoire is anticipated following the recent generous donation from the Millhouse Foundation to facilitate the purchase of an Illumina MiSeq massively parallel sequencing platform, and validation of massively parallel sequencing-based testing for genetic mutations and rearrangements in patients with myeloid malignancies has commenced.
The Molecular Laboratory also actively supports clinical trial research by providing critical molecular data for national trials, including the ALLG M16 trial in FLT3-positive AML, and the ALLG APML5 trial in APL. Additionally, our laboratory is the only Australasian facility that is accredited to perform molecular testing for the international US Children's Oncology Group AAML1331 trial in paediatric APL.
In blood and marrow transplantation, in collaboration with the late Professor Derek Hart and A/Prof Georgina Clark, we have been exploring the kinetics of different cell populations, especially dendritic cells and regulatory T cells, in patients being treated with extra-corporeal photopheresis for the treatment of chronic graft versus host disease. We are also involved with a translational project exploring the use of a monoclonal antibody to CD83 to prevent graft versus host disease.
This has involved collaborating with the Sydney University Baboon colony to perform a successful safety trial, and then a proof of principle trial demonstrating that 3C12C performs mechanistically as expected in a pre-clinical model very similar to humans. This has formed the basis of a Phase 1 clinical trial of 3C12C in allogeneic stem cell transplant patients. We are in final negotiations to raise the funds for this trial and anticipate delivering a clinical product to patients by 2020. This trial will conducted at RPA with A/Prof Larsen as PI and Dr Bryant as clinical scientific lead. In addition, through our collaboration with Prof Hart and A/Prof Clark we have continued to work on cellular vaccines and antibody technology: we have developed a novel strategy to vaccinate patients with acute myeloid leukaemia with blood-derived dendritic cells and developed a new antibody therapy for Hodgkin's and Non-Hodgkin's lymphoma.
One of 2 Australian sites in ground-breaking chimeric antigen receptor T cells treatment in relapsed diffuse large B cell lymphoma, with Prof P Joy Ho as PI, published in the New England Journal of Medicine. This was the first CAR-T trial conducted in Australia and will form the foundation for progress in this field in the immunotherapy of haematological malignancies in this country:
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Tai F, Anak O, Salles G, Maziarz RT. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2018) N Engl J Med 2019; 380:45-56.
Prof H Iland was principal investigator for APML4, the final analysis of which was published in Lancet Haematology.
- APML4 trial combined ATRA, arsenic trioxide and idarubicin for the management of APL, and achieved outstanding success with 95% complete remission, 95% disease-free survival at 5 years, and 94% overall survival at 5 years.
- The APML4 protocol is now recommended by the US National Comprehensive Cancer Network, and also by a panel of Canadian APL experts, for the treatment of high-risk APL
- APML4 results led to approval by the TGA for the use of arsenic trioxide as initial therapy in APL, ahead of both the European and the US regulatory authorities. The PBAC has also recently extended PBS-funding for arsenic trioxide-based therapy in the initial therapy of APL, and that approval was based in part on APML4 data.
- Data from two ALLG trials initiated by Prof Iland (APML3 and APML4) were major components of a multi-centre analysis of the determinants of fatal bleeding during induction therapy for APL, published in Blood. This multivariate analysis highlighted the significance of high white cell count (>20x109/l) as an independent risk factor for early haemorrhagic death
- In a recently initiated major collaboration with Memorial Sloan Kettering Cancer Center (New York, USA), data from APML3 and APML4 are also being combined with US data to assess the impact of cytogenetic abnormalities on the response of APL patients to arsenic-based therapy
- The ALLG APML5 trial, which is the successor to APML4, has been activated nationwide during 2017. Part (i) of the APML5 trial has been completed; successfully, and part (ii) commenced in January 2019. -
Prof Iland's contributions to the management of APL have been acknowledged internationally; he was invited to contribute a chapter on the management of APL to a new textbook specifically dedicated to APL, and he was invited to join the European LeukemiaNet's panel of international APL experts which has recently revised and published guidelines for the diagnosis and management of APL.
Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF for the Australasian Leukaemia and Lymphoma Group. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015; 2(9):e357-66.
Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone RM, Powell BL, Geyer S, Laumann K, Rowe JM, Erba HP, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 2017; 129(13):1763-1767.
Iland H. First-line therapy: ATRA-ATO/reduced chemotherapy approach. In: Acute Promyelocytic Leukemia - A Clinical Guide. O Abla, F Lo-Coco, MA Sanz (eds), Springer Publishing Company, 2018, DOI: 10.1007/978-3-319-64257-4.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Doehner H, Burnett AK, Chen SJ, Mathews V, Iland HJ, Rego E, Kantajian HM, Ades L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, and Lo Coco F. Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet. Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980. [Epub ahead of print]
Prof Joy Ho was principal investigator of an epidemiological study of iron overload in transfusion dependent anaemias and non-transfusion dependent thalassaemia. The study provided new and important insights into the impact of iron toxicity on disease course, and was a major achievement in the integration of improved disease monitoring by cardiac and liver MRI monitoring with innovations in management strategies, and in the assessment of different modes of iron load assessment across benign and malignant transfusion dependent diseases:
Ho PJ, Hiwase D, Ramakrishna R, Viiala N, Ross D, Zor E, Gervasio O, Bowden DK. Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. Accepted for publication in Hemasphere, March 2019.
Prof Joy Ho was the principal investigator at RPA Haematology, the lead Australian investigative site in the trial of Luspatercept which modulates ineffective erythropoiesis. Luspatercept is one of the first disease modifying pharmaceutical agents shown to be effective in thalassemia major and subjected to analysis by a Phase III clinical study; this has been presented at the American Society of Hematology annual meeting in December 2018:
Cappellini MD, Viprakasit V, Taher A, Georgiev P, Kevin Kuo KHM, Coates TD, Voskaridou E, Liew HK, Idit Pazgal-Kobrowski I, Forni G, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, et al. The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell Transfusions. Blood 2018 132:163
Gene therapy of 2 thalassaemia major patients of Prof Joy Ho through the Bluebird bio pivotal trial. RPA Haematology and another site in Thailand were the only non-American clinical sites, enrolling 2 out of the total 18 patients reported in this international gene therapy trial utilising a lentiviral vector .
Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil J-A, Hongeng S, Magrin E, Gary J. Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana J-S, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet J-F, Pondarré C, Yves Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C , Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross R, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M (2018) Gene Therapy for Transfusion-Dependent β?Thalassemia. N Engl J Med 2018; 378:1479-1493.
Prof Joy Ho was also principal investigator for a multi-centre study on the effect of an oral iron chelator on cardiac iron in transfusion-dependent diseases, the most important cause of mortality in patients with the haemoglobinopathies, assessed by state-of-the-art technology of cardiac MRI with T2* quantitation in conjunction with MRI assessment of liver iron:
Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock C, Traficante R, Gervasio OL, Bowden DK. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Hematol 2017; 98(2)97-105.
Invitation of Prof Joy Ho to give plenary lecture on the Myeloma group's investigations into the heterogeneity of terminal effector T cells using high throughput approaches of mass cytometry and single cell transcriptome analysis at the 2nd national Australian Myeloma Workshop, Yarra Valley, Victoria, September 2018. "Dissecting the heterogeneity of CD8+ terminal effector T cells in myeloma". PJ Ho on behalf of Ho, Vuckovic, Bryant, Joshua, Yang et al
In collaboration with colleagues from the Monash University/Alfred Hospital National Multiple Myeloma Registry, Prof Joy Ho has led a project in the review of treatment and outcomes of patients with myeloma presenting with renal failure, leading to presentations at European Society of Hematology and American Society of Hematology annual scientific meetings, 2018. A manuscript is currently in review:
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison S, Horvath N, King T, McNeil JJ, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A (2018). Renal impairment at diagnosis in myeloma: patient characteristics, treatment and impact on outcomes. Results from the Australia and New Zealand Myeloma & Related Diseases Registry. Under review - Clin Lymphoma Myeloma Leuk, 2018-2019
Elucidation of the mechanisms of T cell dysfunction or senescence in myeloma
- Identification of novel targets and key factors in checkpoint blockade in myeloma;
- Characterisation of the mechanisms of tumour-induced inhibition of clonal T cell expansions in multiple myeloma
Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, Gibson J, Joshua D. Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 2016;30:1716-24.
Suen H, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia 2015;29(7):1621-2.
• Christian Bryant awarded Brian D. Novis Junior Research Grant from International Myeloma Foundation ($USA 50.000/2019).
• P. Joy Ho - appointed Chair of the Metrics Sub-Committee of American Society of Hematology (ASH) International Members' Committee in 2018, responsible for evaluating ASH International Programs benefiting international haematology communities - the Visitors' Training Program (VTP), Partnership with Health Volunteers Overseas (HVO) and Latin American Training Program (LATP).
• Harry Iland - Awarded Member of the Order of Australia (AM) for significant service to medicine, and to medical research, in the specialty of haematology, and as a mentor of young scientists (2017)
• P. Joy Ho - appointed by Australian Government as member of Pharmaceutical Benefits Advisory Committee (2017), for a term of 4 years
• Harry Iland - Awarded Robert Pitney Travelling Fellow of the HSANZ for 2015-2016. • Harry Iland - awarded the Carl de Gruchy Orator for HSANZ, 2016
• P. Joy Ho - President of Haematology Society of Australia and New Zealand, 2013-2015
• Hayley Suen - Albert Baikie Memorial Medal for the best oral presentation by an early investigator at the Annual Scientific Meeting for the Haematology Society of Australia and New Zealand in 2015
• Tracy King - President of Nurses Division of HSANZ, 2013-2015
• Tracy King - Chair Nurse Organising Committee International Myeloma Workshop; 2013- ongoing
• Tracy King - Myeloma Australia Volunteer Award for Meritorious Service to the Myeloma Community 2018.
- Prof P. Joy Ho (Director of Research)
- Prof John Gibson (Head of Department)
- A/Prof Christina Brown
- Dr Christian Bryant
- Dr Alberto Catalano
- Dr Scott Dunkley
- Prof Harry Iland
- Ms Alana Johnson
- Prof Doug Joshua
- Ms Karieshma Kabani
- Dr Liane Khoo
- Ms Tracy King
- A/Prof Stephen Larsen
- Dr Derek McCulloch
- Dr Dimitrii Minchenko
- Mr Daniel Orrellana
- Ms Cheryl Paul
- Mr Nicholas Poerio
- Mr Geoffrey Kershaw
- Ms Francisca Supple
- Dr Shane Supple
- Dr Slavica Vuckovic
- Ms Shihong Yang
Clinical Trial Coordinators:
- Ms Jane Higgins, Clincial trials manager
- Ms Louise Brooks, Clinical nurse consultant
- Ms Zara Mills
- Ms Cassandra Redpath
- Ms Alexie Soulos
- Dr Jose Valencia
- A/Prof Georgina Clark
- Prof Barbara Fazekas de St Groth (the late)
- Prof Derek Hart Dr Freda Passam
- Prof John Rasko
- Prof Martin Tallman (MSKCC)
Haematology Specialty Nurses
Higher Degree Students:
- Katrina Debosz - Nurse practitioner; Lymphoma, Transplantation
- Sandra Geddes - Haematology
- Mickael Gieules - Blood transfusion
- Louise Kerr - Transplantation
- Tracy King - Myeloma Paul Malau - Apheresis
- Stephen Matthews - Haemophilia and Thalassaemia/Sickle cell disease
- Eleanor Romney - Myeloma Sally Taylor - Transplantation Janet Varnum - Blood transfusion
- Geoff Kershaw - PhD
- Tracy King - PhD
- Daniel Orellana - MSc & FFSc(RCPA)
- Bernadette Blayney - MSc
- Mark Langshaw - MSc
- Karieshma Kabani - FFSc (RCPA)
- Kristen Piper - MD
- Katrina Debosz - graduated as Nurse Practitioner
- Annabel Kruzins - Honours Student, UTS (enrolling 2018-19)
- Ka Hei Aleks Lau - Honours Student, UTS (enrolling 2019)
- Mickael Gieules - graduate certificate in clinical redesign
Publications and Presentations
1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Tai F, Anak O, Salles G, Maziarz RT. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019) N Engl J Med 380:45-56
2. Thompson AA, Walters MC, Kwiatkowski J, Rasko, JEJ, Ribeil, J-A, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana, J-S, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet J-F, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey, DT, Anurathapan U, Ho PJ et al (2018) Gene therapy in patients with transfusion-dependent beta-thalassemia. New Engl J Med 378:1479-93.
3. Ho PJ, Hiwase D, Ramakrishna R, Viiala N, Ross DM, Solterbeck A, Traficante R, Zor E, Gervasio OL, High L, Bowden DK. Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study. Hemasphere, in press, 2019.
4. Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana DW, McGuire H, Fazekas de St Groth B, Joshua DE, Ho PJ, Larsen SR, Iland HJ, Gibson J, Clark GJ, Fromm PD, Hart DNJ. A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology: e1419114; Published online: 25 Jan 2018.
5. Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX (2018). Haematologica. 2018 Sep 20. pii: haematol.2018.194282. doi: 10.3324/haematol.2018.194282.
6. Anderson SA, Kiernan M, Ho PJ. Lenalidomide related Progressive Multifocal Leukoencephalopathy: Report and review of drug-related cases in multiple myeloma Clin Lymphoma Myeloma Leuk. (2019) Jan 3. pii: S2152-2650(18)31732-4. doi: 10.1016/j.clml.2018.12.021
7. Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL (2018). Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Adv Ther (2018) 35(11):1859-1872.
8. Iland H. First-line therapy: ATRA-ATO/reduced chemotherapy approach. In: Acute Promyelocytic Leukemia - A Clinical Guide. O Abla, F Lo-Coco, MA Sanz (eds), Springer Publishing Company, 2018, DOI: 10.1007/978-3-319-64257-4.
9. Iland HJ. Curative strategies in acute promyelocytic leukemia. Sem Hematol 2018 doi.org/10.1053/j.seminhematol.2018.07.004
10. Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Doehner H, Burnett AK, Chen SJ, Mathews V, Iland HJ, et al. Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet. Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980. [Epub ahead of print]
11. Wirth A, Prince HM, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone JM, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). International Journal of Radiation Oncology 2019 (in press)
12. Clucas D, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J et al, Australian Aplastic Anaemia Registry Steering Committee. Revisiting acquired aplastic anaemia: Current concepts in diagnosis and management. Internal Medicine Journal (2019) 49(2):152-159.
13. Dyer G, Brice L, Gilroy N, Kabir M, Hertzberg M, Greenwood M, Larsen SR, Moore J, Gottlieb D, Huang G, Hogg M, Brown L, Tan J, Ward C, Kerridge I (2018). Changes to work status and household income of long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia. Bone Marrow Transplant. 2018 Jan 29. doi: 10.1038/s41409-018-0098-4. [Epub ahead of print]
14. Kershaw GW, Dissanayake K, Chen VM, Khoo T-L (2018).Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia. 2018;00:1-10.
15. Dunkley S, Lam JCM, John MJ, Wong RSM, Tran H, Yang R, Nair SC, Shima M, Street A, Srivastava A; Asia-Pacific Haemophilia Working Group (APHWG). Principle of haemophilia care: the Asia Pacific perspective. Haemophilia. 2018 May;24(3):366-375
16. Yeung J, Vaughan E, Chadban S, Saunders J, Thiagarajah N, Brown C. High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: a case report. Nephrology. 2018 Nov;23(11):1063-1064. doi: 10.1111/nep.13254.
17. Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 Apr;103(4):655-665.
18. Othman J and Brown C. Talaromyces marneffei and dysplastic neutrophils on blood smear in newly diagnosed HIV. Blood 2018 131:269.
19. Bryant C, Sutherland S, Kong B, Papadimitrious B, Fromm D, Hart D. Dendritic Cells as Cancer Therapeutics. Seminars in Cell and Developmental Biology. 2018 Mar 21. pii: S1084-9521(17)30495-0.
20. Joshua DE, Bryant CE, Gibson J, Ho PJ (2018) Multiple myeloma biology and therapy. Major progress in the last decade. Med J Aus, in press, 2019.
21. McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Menant J, Friedlander M, Lewis CR, Hertzberg M, O'Neill S, King T, Bosco A, Harrison M, Park SB. Balance deficits and disability in cancer survivors exposed to neurotoxic treatments. Journal of the National Comprehensive Cancer Network, in press, 2019.
22. King TA, Jagger J, Wood J, Woodrow C, Snowden A, Haines S, Crosbie C, Houdyk K. (2018) Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. Asia Pac J Oncol Nurs. 5:270-84. DOI: 10.4103/apjon.apjon_9_18.
23. Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, Guillerey C, Engwerda C, MacDonald KPA, Smyth MJ, Markey KA, Vuckovic S, Hill GR. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132:1675-1688.
24. Nakamura K, Kassem S, Cleynen A, Chrétien M-L, Guillerey C, Putz EM, Bald T, Forster I, Vuckovic S et al.. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007.
25. Wilkinson AN, Gartlan KH, Kelly G, Samson LD, Olver SD, Avery J, Zomerdijk N, Tey S-K, Lee JS, Vuckovic S, Hill G. Granulocytes are unresponsive to IL-6 due to an absence of gp130. J Immunol. 2018 May 15;200(10):3547-3555. doi: 10.4049/jimmunol.1701191. Epub 2018 Apr 6.
26. Prestipino, A., Emhardt, A. J., Aumann, K., O'Sullivan, D., Gorantla, S. P., Duquesne, S., Melchinger, W., Braun, L., Vuckovic, S et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.
27. McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. OncoTargets Ther 2017; 10:1585-1601.
28. Kommers IO, Bartley PA, Budgen B, Latham S, Beligaswatte A, Supple SG, Catalano A, Iland HJ, Morley AAM, Ross DM. Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR. Leuk Lymphoma 2017; 58(7):1767-1769.
29. Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone RM, Powell BL, Geyer S, Laumann K, Rowe JM, Erba HP, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 2017; 129(13):1763-1767.
30. Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK (2017) .Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haematol. 98(2)97-105.
31. Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins A, Ross DM. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis (2017). Intern Med J. 47(3):262-268.
32. Quach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end stage renal disease (ESRD): an open-label, single-arm, phase I study (2017). Cancer Chemother Pharmacol. (2017) Jun;79(6):1067-1076.
33. Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P (2017). Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. Leuk Lymphoma 12:1-3.
34. Lee OL, Horvath N, Lee C, Joshua D, Ho PJ, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Intern Med J. 2017 Aug;47(8):938-951.
35. Talaulikar D, Tam CS, Joshua D, Ho PJ, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM (2017). Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 47(1):35-49.
36. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337.
37. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017 Jan;31(1):115-122.
38. Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374.
39. Othman J, Orellana D, Chen LS, Russell M and Khoo T-L (2017). The Presence of F Cells with a Fetal Phenotype in Adults with Hemoglobinopathies Limits the Utility of Flow Cytometry for Quantitation of Fetomaternal Hemorrhage. Cytometry Part B 2017.
40. Satgunaseelan L, Larsen SR, Carmalt H, Cooper WA. Spindle cell variant of diffuse large B cell lymphoma occurring in the breast. Pathology. 2017 Dec;49(7):784-786. doi: 10.1016/j.pathol.2017.06.009. Epub 2017 Oct 24.
41. Kunchok A, Larsen S, Halmagyi GM. Letter re: Primary marginal zone lymphoma of the CNS presenting as a diffuse leptomeningeal process. Neurology. 2017 Mar 7;88(10):1007.
42. Vuckovic S, VandykeS , Rickards DA et al. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. Brit J Haematol, (2017) 177: 423-440.
43. Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, Ullah MA, Vuckovic S et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Science Immunology 07 Apr 2017: Vol. 2, Issue 10, eaah7152,DOI: .1126/sciimmunol.aah7152.
44. Alcheikh A, Lynar S, Brown C, Lee A, Bryant C. Unusual case of splenomegaly and pancytopenia in a returned traveler. Intern Med J. 2017 Nov;47(11):1325-1326
45. Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2017 Sep 22:1-11. doi: 10.1080/10428194.2017.1376743.
46. Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk Lymphoma. 2017 Oct;58(10):2501-2504.
47. Othman J, Robbins E, Lau EM, Mak C, Bryant C. Tattoo pigment-induced granulomatous lymphadenopathy mimicking lymphoma. Ann Intern Med. 2017 Dec 5;167(11):830-831. doi: 10.7326/L17-0424. Epub 2017 Oct 3.
48. King T, King, M, White K. (2017) Patient Reported Outcomes in Optimizing Myeloma Patients' Health-Related Quality of Life. Seminars in Oncology Nursing. 33:299-315 DOI 10.1016/j.soncn.2017.05.006
49. King T, Faiman B. (2017). A Review of Steroid-Associated Side Effects and Important Considerations in Multiple Myeloma: A Symptom Management Update on behalf of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology 21(2):240-249. DOI:10.1188/17.CJON.240-249
50. B Faiman, Doss, D., Colson K, Mangan P, T King, J Tariman, (2017) On behalf of the International Myeloma Foundation Nurse Leadership Board. Evidence-Based Recommendations for Renal, Gastrointestinal and Peripheral Nerve-Related Symptoms Management: An Update from the 2008 IMF Nurse Leadership Board Consensus Guidelines for the Care of Patients with Multiple Myeloma. Clinical Journal of Oncology Nursing. 21(5supp):19-36
1. P. Joy Ho: Dissecting the Heterogeneity in Terminal Effector CD8+ T cells in myeloma; Plenary lecture at the 2nd Australian Myeloma Workshop, Yarra Valley, Victoria, 2018.
2. Vuckovic S. Dissecting the Heterogeneity in Terminal Effector CD8+T Cells in Multiple Myeloma; Dendritic Cell Down Under Symposium, Sydney, 2018.
3. Ho PJ, Weisel K, Siegel D, San Miguel JF, Hajek R, Gaidano G,Orlowski RZ, Zhou L, Kimball AS, Moreau P. Overall survival with carfilzomib/dexamethasone (Kd56) versus bortezomib/dexamethasone (Vd) by prior line of therapy and previous exposure to bortezomib, Haematology Society of Australia and New Zealand Annual Scientific Meeting (BLOOD 2018), Brisbane 2018; Presidential Symposium.
4. Ho PJ, Michele Cavo M,2 Meletios A. Dimopoulos MA,3 Jesus San-Miguel J,4 Andrzej Jakubowiak A, Suzuki K, Yoon SS, Cook M,8 Mario Boccadoro M, Pour L, Knop S, Doyen C, Crepaldi A, Masszi T, Bladé J, Wang J, Wroblewski S, Deraedt W, Qi M, Mateos M-V. Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone in Transplant-ineligible Newly Diagnosed Multiple Myeloma (ALCYONE) .Haematology Society of Australia and New Zealand Annual Scientific Meeting (BLOOD 2018), Brisbane 2018
5. P. Joy Ho: Immunotherapy in RPA Haematology: the present and the future. Sydney Catalyst Lecture, August 2018.
6. P. Joy Ho - Advances in the Management of the Haemoglobinopathies - Haematology Society of Australia and New Zealand, New Zealand Branch Annual Scientific Meeting, Plenary lecture, Wellington, April 2018.
7. Catalano A, Minchenko D, Poerio N, Springall F, Supple S, Johnson A, Paul C, Iland H. Demographic analysis of cases referred for investigation of FIP1L1-PDGFRA positive chronic eosinophilic leukaemia (CEL) in Australia. Haematology Society of Australia and New Zealand Annual Scientific Meeting (BLOOD 2018), Brisbane 2018.
8. Pillay N, Chai S, Horan M, Iland H, Bennetts B, Badrick T. Evaluation of diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukaemia. Haematology Society of Australia and New Zealand Annual Scientific Meeting (BLOOD 2018), Brisbane 2018.
9. Meyer N, Gieules M, Blayney B, Ackerman L, Gibson J, Khoo L (2018) "Fibrinogen concentrates versus blood products in critical bleeding: a systematic review and experience of massive transfusion in a tertiary referral hospital [abstract]" Presented at Blood 2018 Annual Scientific Meeting October 21-24 Abstract n#145.
10. Malau P. CAR T Cell Therapy for B Cell Malignancy: Collection, Reinfusion and Management of Side Effects. Symposium of cellular Therapy, Therapeutic Apheresis and Transfusion Medicine. 4th Regional Thrombosis Hemostasis Symposium, Indonesian Society of Thrombosis. March 2018 Medan Indonesia.
11. Malau P. Lymphocyte Collection for CAR T Cells. NSW Agency for Clinical Innovation. Webinar Feb 2018.
12. King T. Development and evaluation of a patient reported outcome measure (PROM) to assess the impact of steroids associated with therapy for multiple myeloma (MM). International Myeloma Foundation Nurse Leadership Board Meeting 2018. Las Vegas USA.
13. King T Managing disease and treatment related effects in those living with myeloma. Myeloma. Australia and Leukaemia Foundation National Myeloma Seminar, Sydney May 2018 Aus. Invited speaker
14. Iland H. The ALLG approach to incorporating arsenic trioxide - APML4 (final analysis) and APML5 (encapsulating therapy). Clinical Plenary Session of the 7th International APL Symposium, Rome 2017.
15. Ho PJ (2017) Emerging Therapies in Thalassemia. Plenary Lecture at the Singapore Society of Haematology Annual Scientific Conference, May 2017.
16. Ho PJ, Moore E, McQuilten Z, Bergin K, Augustson B, Blacklock H, Horvath N, King T, McNeil J, Mollee P,Quach H, Reid C, Rosengarten B, Walker P, Wood E, Spencer A (2017) Renal impairment in myeloma: patient characteristics, treatment modalities, stem cell transplant & outcomes from the Australia and New Zealand Myeloma & Related Diseases Registry. European Hematology Association (EHA) Annual Scientific Conference, 2017.
17. Ho PJ, Niesvizky R, Hungria V, White DJ, Zhou L, Iskander KS, Rosiñol L (2017) Peripheral neuropathy in relapsed/refractory myeloma treated with carfilzomib vs comparators in Phase 3 trials. HAA (Haematology Society of Australia & New Zealand) Annual Scientific Meeting, 2017.
18. King, T. How does myeloma impact Health Related Quality of Life (HRQoL): the patient perspective. HAA Oct 2017 Sydney Aus. Invited Speaker.
19. King T. Nurses role in delivering best supportive care: Australian Experience. Multiple Myeloma Nurse and Pharmacist Education Workshop. Sept 2017 Bangkok Thailand. Invited Speaker.
20. King T, Sipavicius J. myeNURSE: development and use of an e-portal for nurses to share best practice and information resources at the point of service. International Myeloma Workshop March 2017 Delhi India. Accepted oral.
21. King T. Chair and Organiser. The Role of Education and Information: Patient, caregivers and nurses. International Myeloma Nurses Workshop. All India Institute of Medical Sciences (AIIMS) & Oncology Nurses Association of India, Feb 2017 Delhi, India.
22. King T Nursing Management of Myeloma Related Effects. Seminars In Multiple Myeloma. Tata Memorial Hospital & Oncology Nurses Association of India, Feb 2017 Mumbai, India.
23. Taylor S 'Whose dose is it anyway? The legal, medical and nursing implications relating to delivery of cancer therapy. Chair, panel member. HAA October 2017 Sydney.
24. Klement E, Hartmann E, Goujart MA, Betton D, Descloux E, Merlet A, Macheda G, Amedeo N, Brown C; Gibson J, Larsen S, Ho PJ, Cazorla C. Dix ans de Myélome en Nouvelle Calédonie : épidémiologie et prise en charge. 39e Congres de la Societe Francaise d'Hematologie, Paris, 2019.
Grant total $
Millhouse Foundation Grant 2018
C Bryant, PJ Ho, S Vuckovic, J Gibson
Fortessa 18-colour Flow Cytometer for Myeloma Research
Millhouse Foundation Grant 2018
H. Iland, D McCulloch, PJ Ho, C Bryant, J Gibson
Illumina Next Generation Sequencer.
CIA: Hayley Suen
CIB: Joy Ho
CIC: John Gibson
CID: Douglas Joshua
CIE: Christian Bryant
CIF: Derek Hart
Restoring the Function of Clonal Cytotoxic T cells in Multiple Myeloma to Develop Novel Therapies and Define the Antigenic Landscape
CIA – Peter Croucher
CIB - Michelle McDonald
CIC – Tri Phan
CID – P. Joy Ho
CIE – Paul Baldock
Anti-Sclerostin – a novel, dual action agent to treat multiple myeloma.
AHCDO (Australian Haemophilia Centre Directors Organisation)
Grant to conduct a study examining the role of chromogenic FIX assay in (i) measuring FIX levels in haemophilia B patients to determine if there is a group of patients with discrepant results and (ii) comparison of this new assay with the one stage assay in measuring FIX levels in the spiked samples.
Contact details for department
Head of Department: Professor P. Joy Ho (Director of Research)
Department/Unit: Institute of Haematology
Telephone: (02) 9515 8031
Facsimile: (02) 9515 6698